Get the Stockscreener App
57.45
1.61%
-0.935
Vaxcyte Inc stock is traded at $57.45, with a volume of 297.16K.
It is down -1.61% in the last 24 hours and up +21.30% over the past month.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
See More
Previous Close:
$58.39
Open:
$57.76
24h Volume:
297.16K
Relative Volume:
0.19
Market Cap:
$8.30B
Revenue:
-
Net Income/Loss:
$-946.53M
P/E Ratio:
-8.2474
EPS:
-6.9664
Net Cash Flow:
$-814.94M
1W Performance:
-0.47%
1M Performance:
+21.30%
6M Performance:
+28.09%
1Y Performance:
+72.78%
1-Day Range:
$56.55
$58.31
1-Week Range:
$55.38
$59.49
52-Week Range:
$29.08
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
57.45 | 8.39B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
528.23 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.45 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
926.34 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.28 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Reiterated | Needham | Buy |
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
PCVX (NASDAQ) director reported three 2,250-share sales and RSU/option items - Stock Titan
Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell 2500 Growth Benchmark - marketscreener.com
10 Health Care Stocks With Whale Alerts In Today’s Session - Benzinga
Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell 2000 Growth Benchmark - marketscreener.com
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a Potential 92.85% Upside in the Biotech Sector - DirectorsTalk Interviews
Vaxcyte, Inc.(NasdaqGS: PCVX) added to Russell 3000E Growth Benchmark - marketscreener.com
Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing - marketscreener.com
Is Vaxcyte’s (PCVX) Russell Index Debut Quietly Reframing Its Long‑Term Governance And Growth Story? - simplywall.st
Price to sales forward of Vaxcyte, Inc. – NASDAQ:PCVX - TradingView
Understanding Momentum Shifts in (PCVX) - Stock Traders Daily
Enterprise value to EBIT forward of Vaxcyte, Inc. – NASDAQ:PCVX - TradingView
Enterprise value to EBIT forward of Vaxcyte, Inc. – XETR:5VA - TradingView
Price to sales forward of Vaxcyte, Inc. – XETR:5VA - TradingView
Price to earnings forward of Vaxcyte, Inc. – NASDAQ:PCVX - TradingView
Enterprise value to EBITDA forward of Vaxcyte, Inc. – NASDAQ:PCVX - TradingView
Price to earnings forward of Vaxcyte, Inc. – XETR:5VA - TradingView
Price to book forward of Vaxcyte, Inc. – XETR:5VA - TradingView
Vaxcyte CEO Grant Pickering sells $1.34m in company shares By Investing.com - Investing.com India
Vaxcyte CEO Grant Pickering sells $1.34m in company shares - Investing.com UK
Form 144 Vaxcyte For: 26 June By Investing.com - Investing.com South Africa
Form 4 Vaxcyte Inc For: 26 June By Investing.com - Investing.com Nigeria
Vaxcyte (PCVX) CEO and family trusts sell 24,237 shares under 10b5-1 plan - Stock Titan
PCVX Forecast — Price Target — Prediction for 2027 - TradingView
Grant Pickering sells 22,461 PCVX shares (UBS broker) (PCVX) - Stock Titan
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110 - Moomoo
Vaxcyte, Inc. Actuals & Estimates (NASDAQ:PCVX) - TradingView
Vaxcyte Company Profile & Introduction - Moomoo
Vaxcyte, Inc. Actuals & Estimates (XETR:5VA) - TradingView
5VA Forecast — Price Target — Prediction for 2027 - TradingView
Vaxcyte announces board changes with retirement of Jacks Lee and appointment of Moncef Slaoui By Investing.com - Investing.com India
Vaxcyte announces board changes with retirement of Jacks Lee and appointment of Moncef Slaoui - Investing.com South Africa
Form 8K Vaxcyte Inc For: 23 June - Investing.com UK
Form 8K Vaxcyte Inc For: 23 June By Investing.com - Investing.com Australia
Vaxcyte Announces Board Transition and New Director Appointment - TipRanks
Moncef Slaoui gets 26,061 Vaxcyte (PCVX) options at $52.11 strike - Stock Titan
Vaxcyte (PCVX) director Moncef Slaoui files Form 3 reporting zero share ownership - Stock Titan
Moncef Slaoui joins Vaxcyte (NASDAQ: PCVX) board as director - Stock Titan
Vaxcyte, Inc. Announces Board Changes, Effective June 17, 2026 - marketscreener.com
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine - Yahoo Finance
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring The 111.90% Potential Upside For Investors - DirectorsTalk Interviews
Vaxcyte Insider Sold Shares Worth $1,284,205, According to a Recent SEC Filing - marketscreener.com
Vaxcyte StockSunday background on a late-stage vaccine developer - Ad-hoc-news.de
Vaxcyte CEO Grant Pickering sells $1.28m in stock By Investing.com - Investing.com UK
Vaxcyte president and CFO sells $530,000 in company stock - Investing.com UK
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vaxcyte Inc Stock (PCVX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Jun 26 '26 |
Sale |
55.21 |
22,237 |
1,227,805 |
452,466 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Jun 26 '26 |
Sale |
55.23 |
2,000 |
110,465 |
134,215 |
0.72%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):